Pacira BioSciences, Inc.

PCRX | $25.93 -3.28% -3.39% 360K

(0.0% 1d) (-8.3% 1m) (-39.6% 1y) (0.0% 2d) (2.7% 3d) (2.1% 7d) (32.5% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,206,346,187
http://www.pacira.com
Sec Filling | Patents | 606 employees

(US) Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

opioid injection

add to watch list Paper trade email alert is off

Press-releases

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -12.27% | O: 0.03% H: 1.24% C: -0.92%
pcrx-201 osteoarthritis granted treatment designation therapy

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
Published: 2024-03-06 (Crawled : 13:00) - globenewswire.com
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -8.93% | O: 0.2% H: 2.22% C: 2.07%
conference global

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -10.36% | O: -1.54% H: 3.63% C: 0.92%
financial results

Pacira to Report 2023 Financial Results on Thursday February 29, 2024
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -9.73% | O: 0.17% H: 0.77% C: 0.74%
report financial results

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
Published: 2024-02-15 (Crawled : 13:30) - globenewswire.com
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -8.28% | O: 0.75% H: 1.63% C: 0.71%
publication study

Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
PINC | $21.125 0.45% 0.45% 1.2M

Health Services

| -2.32% | O: 0.51% H: 2.08% C: -1.62%
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -12.9% | O: -2.08% H: 0.03% C: -5.47%
pharmaceuticals agreement

Amateur Pickleball's Big Game, G.O.A.T. Bowl I, Announces Format and Schedule for Friday, Feb. 9, in Las Vegas
Published: 2024-01-18 (Crawled : 19:00) - prnewswire.com
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -15.51% | O: 0.19% H: 0.31% C: 0.16%

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
Published: 2024-01-04 (Crawled : 22:00) - globenewswire.com
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -17.3% | O: -0.56% H: 8.13% C: 6.3%

Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 13:00) - globenewswire.com
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -16.22% | O: 0.59% H: 1.04% C: -0.37%
conference

Pacira Appoints Frank D. Lee as Chief Executive Officer
Published: 2023-12-21 (Crawled : 12:30) - globenewswire.com
BOLT | $1.19 7.21% 6.72% 150K

| 9.9% | O: 0.0% H: 5.94% C: -1.47%
PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

| -16.76% | O: 0.09% H: 3.5% C: 2.26%

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001396814-24-000014	4	2024-01-04	2024-01-02	Sell	F	159	22528
0001396814-24-000013	4	2024-01-04	2024-01-03	Buy	A	10000	10000
0001396814-24-000013	4	2024-01-04	2024-01-02	Buy	A	5000	51196